


## IN THE CLAIMS

Claims 1-21 (canceled)

22. (currently amended) A method of treating a host having a flavivirus or rhabdovirus infection, which method comprises administering to the host effective amounts of:

- (a) an interferon, and
- (b) at least one compound selected from the group consisting of:
  - 5-membered cyclic nucleosides having the formula (I):




RECEIVED

NOV 05 2003

TECH CENTER 1600/2900


wherein  $[[*X*]] - X -$  is  $=CH-$ ,  $-CH_2-$  or  $-O-$ , Nu is selected from the group consisting of purines, pyrimidines and five- or six-membered aglycones,  $R_2$  and  $R_3$  are independently selected from the group consisting of H, OH, O-acyl, O-aryl and O-silyl, and  $R_1$  is as defined for  $R_2$  and  $R_3$  or is O-phosphate, and pharmaceutically acceptable metabolites, metabolite derivatives and salts thereof;

- mycophenolic acid compounds having the formula (II):




wherein  $R_4$  is  $-OR_6$  or  $-N(R_7)R_8$  in which  $R_6$ ,  $R_7$  and  $R_8$  are independently selected from the group consisting of hydrogen and  $C_1$ - $C_6$  alkyl, and  $R_5$  is selected from the group consisting of hydrogen, phenyl and  $C_1$ - $C_6$  alkyl unsubstituted or substituted by a five- or six-membered saturated or unsaturated heterocyclic ring, and pharmaceutically acceptable salts thereof;

- imidazole derivatives represented by formula (III):




wherein  $R_9$  is a hydrogen atom or




wherein  $R_{10}$  is a hydrogen atom,  $C_1$ - $C_6$  alkyl, hydroxy( $C_1$ - $C_6$  alkyl) or phenyl,  $R_{11}$  and  $R_{13}$  are independently selected from hydrogen and  $OR_{12}$  and  $R_{12}$  is a hydrogen atom or a hydroxy protecting group and  $A$  is  $CONH_2$  or  $CN$ , and pharmaceutically acceptable salts thereof;

- aminoadamantanes having the formula (IV):




wherein each of  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  and  $R_{17}$  is independently selected from the group consisting of H, F and  $CH_3$  and X is  $N(R_{18})_2$ ,  $CH_2CH_2N(R_{18})_2$  or  $C(R_{19})_2N(R_{18})_2$  wherein each  $R_{18}$  and  $R_{19}$  is H,  $(C_1-C_6)$  alkyl,  $(C_6-C_{10})$  aryl and  $(C_7-C_{18})$  aralkyl; and

2,4-diaminopyrimidines having the formula (V):



wherein  $R_{20}$  is phenyl substituted by one or more substituents selected from the group consisting of benzyl,  $NO_2$ ,  $(C_1-C_6)$  alkylamino and halogen and  $R_{21}$  is H or  $C_1-C_6$  alkyl; or  $R_{20}$  and  $R_{21}$  form, together with the 2,4-diaminopyrimidine ring to which they are attached, a quinazoline derivative of formula (V'):



wherein Z is  $-CH_2NR_{23}-$  or  $-NR_{23}CH_2-$ ;  $R_{22}$ ,  $R_{23}$  and  $R_{24}$  are each, independently, H or  $C_1-C_6$  alkyl; and n is 1 or 2, and pharmaceutically acceptable salts thereof.

23. (previously presented) A method according to claim 22, wherein the flavivirus is selected from yellow fever virus, kunjin virus, dengue virus, hepatitis C virus, St. Louis

encephalitis virus, Japanese encephalitis virus, Murray valley encephalitis virus and tick-borne encephalitis virus.

24. (previously presented) A method according to claim 22, wherein the rhabdovirus is selected from vesicular stomatitis virus (VSV) and rabies virus.

25. (previously presented) A method according to claim 22, wherein the interferon (a) is a human interferon.

26. (previously presented) A method according to claim 22, wherein the interferon is selected from interferon  $\alpha 2$ , interferon  $\alpha 8$  and interferon  $\beta$ .

27. (previously presented) A method according to claim 26, wherein the interferon is human interferon  $\alpha 8$  having a specific activity of from  $0.6 \times 10^9$  to  $1.5 \times 10^9$  IU per mg protein.

28. (previously presented) A method according to claim 26, wherein the interferon is human interferon  $\beta$  having a specific activity of from  $4 \times 10^8$  to  $8 \times 10^8$  per mg protein.

29. (currently amended) A method according to claim 22, wherein the compound (b) is at least one compound selected from the group consisting of cyclopentenyl cytosine, mycophenolic acid, 5-ethynyl-1- $\beta$ -D-ribofuranosylimidazole-4-carboxamide, amantadine hydrochloride, 3-deazaneplanocin, neplanocin A, 3-deazauridine, 6-azauridine, aristeromycin, pyrazofurin, tiazafurin, selenofurin, NSC 382046, NSC 7364, NSC 302325, NSC 184692D and NSC 382034.

30. (withdrawn) Products containing an interferon and at least one compound (b) as defined in claim 22 as a combined preparation for simultaneous, separate or sequential use in treating a flavivirus or rhabdovirus infection.

Claims 31-37 (canceled)

38. (previously presented) A method of treating a host having a flavivirus or rhabdovirus infection, which method comprises the step of administering to the host, in respective amounts which produce a synergistic antiviral or antirhabdoviral effect, an interferon and at least one compound (b) as defined in claim 22.

39. (withdrawn) An agent for use in the treatment of a flavivirus or rhabdovirus infection, which comprises an interferon and at least one compound (b) as defined in claim 22.